Lyell Immunopharma Inc. (LYEL)
NASDAQ: LYEL
· Real-Time Price · USD
12.15
0.43 (3.67%)
At close: Sep 05, 2025, 3:59 PM
12.15
0.00%
After-hours: Sep 05, 2025, 04:10 PM EDT
3.67% (1D)
| Bid | 9.95 |
| Market Cap | 233.42M |
| Revenue (ttm) | 60K |
| Net Income (ttm) | -331.4M |
| EPS (ttm) | -24.26 |
| PE Ratio (ttm) | -0.5 |
| Forward PE | -0.97 |
| Analyst | Hold |
| Ask | 14.48 |
| Volume | 18,300 |
| Avg. Volume (20D) | 96,506 |
| Open | 11.51 |
| Previous Close | 11.72 |
| Day's Range | 11.51 - 12.26 |
| 52-Week Range | 7.65 - 32.00 |
| Beta | -0.20 |
About LYEL
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol LYEL
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for LYEL stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts1 month ago
+19.31%
Lyell Immunopharma shares are trading higher after...
Unlock content with
Pro Subscription
10 months ago
+19.35%
Lyell Immunopharma shares are trading higher. The stock may be moving on continued strength after the company announced yesterday it will present clinical data from its Phase 1-2 trial of IMPT-314 CAR T-cell therapy for B-cell lymphoma at ASH 2024.
